BR112013005792A2 - método para o tratamento concomitante de teofilina e febuxostat - Google Patents
método para o tratamento concomitante de teofilina e febuxostatInfo
- Publication number
- BR112013005792A2 BR112013005792A2 BR112013005792A BR112013005792A BR112013005792A2 BR 112013005792 A2 BR112013005792 A2 BR 112013005792A2 BR 112013005792 A BR112013005792 A BR 112013005792A BR 112013005792 A BR112013005792 A BR 112013005792A BR 112013005792 A2 BR112013005792 A2 BR 112013005792A2
- Authority
- BR
- Brazil
- Prior art keywords
- theophylline
- febuxostat
- concomitant treatment
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método para o tratamento concomitante de teofilina e febuxostat. a presente revelação está relacionada a um método de tratamento de hiperuricemia em um paciente que também sofre de um segundo estado de doença que requer tratamento com teofilina, em que o paciente recebe tratamento concomitante com um inibidor de xantina oxidorredutase e teofilina sem resultar em toxicidade por teofilina recomendada pelo fabricante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38148210P | 2010-09-10 | 2010-09-10 | |
PCT/US2011/050870 WO2012033941A1 (en) | 2010-09-10 | 2011-09-08 | Methods for concomitant treatment of theophylline and febuxostat |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013005792A2 true BR112013005792A2 (pt) | 2016-05-03 |
BR112013005792A8 BR112013005792A8 (pt) | 2018-05-08 |
Family
ID=44653592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013005792A BR112013005792A8 (pt) | 2010-09-10 | 2011-09-08 | métodos para o tratamento concomitante de teofilina e febuxostat |
Country Status (12)
Country | Link |
---|---|
US (3) | US9107912B2 (pt) |
EP (1) | EP2613780B1 (pt) |
JP (1) | JP5978216B2 (pt) |
KR (1) | KR101797936B1 (pt) |
CN (1) | CN103298466B (pt) |
AU (1) | AU2011299153B2 (pt) |
BR (1) | BR112013005792A8 (pt) |
CA (1) | CA2812034C (pt) |
ES (1) | ES2532210T3 (pt) |
HK (1) | HK1189170A1 (pt) |
RU (1) | RU2013109380A (pt) |
WO (1) | WO2012033941A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1883405A4 (en) * | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
CA2617248C (en) * | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
WO2008064015A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
MX2009007680A (es) * | 2007-01-19 | 2011-08-03 | Takeda Pharmaceuticals North America Inc | Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios. |
US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
AU2011299153B2 (en) | 2010-09-10 | 2014-10-30 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
CN103862983B (zh) * | 2012-12-12 | 2016-12-21 | 石狮市冠鑫反光材料有限公司 | 3d立体画制作工艺 |
ES2552706B1 (es) * | 2014-05-29 | 2016-09-13 | Universitat De Les Illes Balears | La teobromina y sus derivados para el tratamiento o prevenciónde la litiasis renal |
KR102133290B1 (ko) * | 2018-10-23 | 2020-07-13 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3079303A (en) | 1958-12-11 | 1963-02-26 | Smith Kline French Lab | Basic tablet granulation and process of using same |
US4058614A (en) | 1973-12-04 | 1977-11-15 | Merck & Co., Inc. | Substituted imidazole compounds and therapeutic compositions therewith |
US4296122A (en) | 1975-07-09 | 1981-10-20 | Merck & Co., Inc. | 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids |
DE2707268A1 (de) | 1977-02-19 | 1978-08-31 | Hoechst Ag | Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung |
DE2707270A1 (de) | 1977-02-19 | 1978-08-24 | Hoechst Ag | Pyrazolo-diazepine und verfahren zu ihrer herstellung |
DE2707269A1 (de) | 1977-02-19 | 1978-08-24 | Hoechst Ag | Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung |
DE2727802A1 (de) | 1977-06-21 | 1979-04-19 | Hoechst Ag | Sulfamoyl-arylketone und verfahren zu ihrer herstellung |
JPS5936919B2 (ja) | 1978-10-14 | 1984-09-06 | 日本新薬株式会社 | インド−ル誘導体 |
DE3112116A1 (de) * | 1981-03-27 | 1982-11-04 | Mundipharma GmbH, 6250 Limburg | "arzneimittel" |
US4510322A (en) | 1981-07-13 | 1985-04-09 | Merck & Co., Inc. | Indacrinone having enhanced uricosuric |
DE3232922A1 (de) | 1982-09-04 | 1984-03-08 | Hoechst Ag, 6230 Frankfurt | Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen |
US4632930A (en) | 1984-11-30 | 1986-12-30 | E. I. Du Pont De Nemours And Company | Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives |
US5047246A (en) | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
JPH0366669A (ja) | 1989-08-03 | 1991-03-22 | Shionogi & Co Ltd | 複素環式化合物 |
CA2073981C (en) | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
WO1993004688A1 (en) | 1991-09-09 | 1993-03-18 | Warner-Lambert Company | Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist |
US5358961A (en) | 1991-11-30 | 1994-10-25 | Jin Ro Limited | Pyrrolidine derivatives |
JP2706037B2 (ja) | 1993-04-13 | 1998-01-28 | 帝人株式会社 | シアノ化合物およびその製造方法 |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
JPH07242694A (ja) | 1994-02-28 | 1995-09-19 | Yamasa Shoyu Co Ltd | トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体 |
US6037344A (en) | 1994-08-17 | 2000-03-14 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
US5770601A (en) | 1994-08-17 | 1998-06-23 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
US5514681A (en) | 1994-08-17 | 1996-05-07 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
AUPM835394A0 (en) | 1994-09-23 | 1994-10-13 | King, Michael G. Dr. | Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need |
CA2213420A1 (en) | 1995-02-21 | 1996-08-29 | Kazuki Endo | Purine compounds and xanthine oxidase inhibitors |
US6084147A (en) | 1995-03-17 | 2000-07-04 | Studsvik, Inc. | Pyrolytic decomposition of organic wastes |
ES2224160T3 (es) | 1995-04-07 | 2005-03-01 | Teijin Limited | Agente protector para organo o tejido. |
JPH1045773A (ja) | 1996-08-07 | 1998-02-17 | Daicel Chem Ind Ltd | リン含有化合物およびその製造方法 |
ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
US5965625A (en) | 1997-03-21 | 1999-10-12 | King; Michael Glenn | Compositions and methods for the control of smoking |
WO1999024038A1 (en) | 1997-11-07 | 1999-05-20 | Johns Hopkins University | Methods for treatment of disorders of cardiac contractility |
JPH11140086A (ja) | 1997-11-07 | 1999-05-25 | Yamasa Shoyu Co Ltd | 4−置換−1H−6−オキソピラゾロ[3,4−d]ピリミジン化合物及びキサンチンオキシダーゼ阻害剤 |
PL200710B1 (pl) | 1998-06-19 | 2009-01-30 | Teijin Pharma Ltd | Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania |
BRPI9912974B8 (pt) | 1998-08-06 | 2021-05-25 | Univ Duke | conjugados de peg-urato oxidase e seu uso |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
US6372246B1 (en) | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
US6281222B1 (en) | 1999-08-19 | 2001-08-28 | Inotek Corporation | Compositions and method for treatment of acetaminophen intoxication |
ECSP993280A (es) | 1999-12-17 | 2001-07-27 | Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos | |
JP2004517804A (ja) | 2000-06-28 | 2004-06-17 | メルク・アンド・カンパニー・インコーポレーテッド | 心臓血管病の治療法 |
JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
ITMI20010206A1 (it) | 2001-02-02 | 2002-08-02 | Dompe Spa | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
BR0209133A (pt) | 2001-04-18 | 2004-06-15 | Genzyme Corp | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
WO2002085380A1 (en) | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for treating gout and reducing serum uric acid |
US20050014805A1 (en) | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
CN1561340B (zh) | 2002-01-28 | 2012-05-23 | 株式会社富士药品 | 1,2,4-三唑类化合物 |
KR100981905B1 (ko) | 2002-03-28 | 2010-09-13 | 데이진 화-마 가부시키가이샤 | 단일 결정형을 함유하는 고형제제 |
US20060040945A1 (en) | 2002-05-17 | 2006-02-23 | Merckle Gmbh | Annellated pyrrole compounds as proton pump inhibitors for treating ulcer |
US7078423B2 (en) | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
US20040121004A1 (en) | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
US20040131676A1 (en) | 2002-12-20 | 2004-07-08 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
WO2005018635A2 (en) | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
WO2006028342A1 (en) | 2004-09-06 | 2006-03-16 | Biosynergen, Inc. | A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same |
CA2587558A1 (en) | 2004-11-19 | 2006-05-26 | Shiva Biomedical, Llc | Methods of treating erythropoietin-resistance |
EP1883405A4 (en) | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
CA2617248C (en) | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
WO2007062028A2 (en) | 2005-11-21 | 2007-05-31 | Tap Pharmaceutical Products, Inc. | Treatment of qt interval prolongation and diseases associated therewith |
US20090124623A1 (en) | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
WO2008064015A1 (en) | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
MX2009007680A (es) * | 2007-01-19 | 2011-08-03 | Takeda Pharmaceuticals North America Inc | Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios. |
MX2007011927A (es) | 2007-09-26 | 2009-03-26 | World Trade Imp Export Wtie Ag | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. |
US20100311756A1 (en) | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
SG186798A1 (en) | 2010-06-25 | 2013-02-28 | Teijin Pharma Ltd | Sustained-release therapeutic agent for hypertension and renal dysfunction |
NZ605562A (en) | 2010-07-09 | 2013-11-29 | Teijin Pharma Ltd | Deuterated benzylbenzene derivatives and methods of use |
AU2011299153B2 (en) | 2010-09-10 | 2014-10-30 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
-
2011
- 2011-09-08 AU AU2011299153A patent/AU2011299153B2/en not_active Ceased
- 2011-09-08 BR BR112013005792A patent/BR112013005792A8/pt not_active Application Discontinuation
- 2011-09-08 RU RU2013109380/15A patent/RU2013109380A/ru unknown
- 2011-09-08 CN CN201180054390.5A patent/CN103298466B/zh not_active Expired - Fee Related
- 2011-09-08 ES ES11758053.0T patent/ES2532210T3/es active Active
- 2011-09-08 EP EP20110758053 patent/EP2613780B1/en not_active Revoked
- 2011-09-08 WO PCT/US2011/050870 patent/WO2012033941A1/en active Application Filing
- 2011-09-08 KR KR1020137009027A patent/KR101797936B1/ko active IP Right Grant
- 2011-09-08 JP JP2013528294A patent/JP5978216B2/ja active Active
- 2011-09-08 CA CA2812034A patent/CA2812034C/en not_active Expired - Fee Related
- 2011-09-08 US US13/227,828 patent/US9107912B2/en active Active
- 2011-10-27 US US13/282,659 patent/US20120065207A1/en not_active Abandoned
- 2011-11-14 US US13/295,696 patent/US8372872B2/en active Active
-
2014
- 2014-03-06 HK HK14102283.6A patent/HK1189170A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8372872B2 (en) | 2013-02-12 |
WO2012033941A1 (en) | 2012-03-15 |
BR112013005792A8 (pt) | 2018-05-08 |
CA2812034C (en) | 2018-10-23 |
EP2613780B1 (en) | 2014-11-12 |
JP5978216B2 (ja) | 2016-08-24 |
US20120065215A1 (en) | 2012-03-15 |
RU2013109380A (ru) | 2014-10-20 |
KR20130097775A (ko) | 2013-09-03 |
AU2011299153B2 (en) | 2014-10-30 |
CN103298466B (zh) | 2015-11-25 |
AU2011299153A1 (en) | 2013-03-07 |
CN103298466A (zh) | 2013-09-11 |
US20120065236A1 (en) | 2012-03-15 |
ES2532210T3 (es) | 2015-03-25 |
JP2013539747A (ja) | 2013-10-28 |
CA2812034A1 (en) | 2012-03-15 |
HK1189170A1 (zh) | 2014-05-30 |
US20120065207A1 (en) | 2012-03-15 |
EP2613780A1 (en) | 2013-07-17 |
US9107912B2 (en) | 2015-08-18 |
KR101797936B1 (ko) | 2017-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013005792A2 (pt) | método para o tratamento concomitante de teofilina e febuxostat | |
UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
MX2019001198A (es) | Activadores de moleculas pequeñas de funcion de la enzima parkin. | |
BR112015028879A2 (pt) | derivados heterocíclicos | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
ECSP13012719A (es) | Compuesto bicíclico | |
BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
MY169328A (en) | Compositions for the treatment of dry eye | |
EA201100302A1 (ru) | Лечение диабета у пациентов, для которых лечение метформином является неприемлемым | |
MX2010006203A (es) | Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina. | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
IN2012DN01641A (pt) | ||
BR112013001296A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
IN2012DN01642A (pt) | ||
GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
BR112014011223A2 (pt) | método de tratar uma doença proliferativa | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |